Literature DB >> 16000334

Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset.

Stefan-M Pulst1, Nieves Santos, Dai Wang, Huiying Yang, Duong Huynh, Luis Velazquez, K Pattie Figueroa.   

Abstract

Nine neurodegenerative diseases, collectively referred to as polyglutamine (polyQ) diseases, are caused by expansion of a coding CAG DNA trinucleotide repeat. PolyQ diseases show a strong inverse correlation between CAG repeat length and age of disease onset (AO). Despite this, individuals with identical repeat expansion alleles can have highly variable disease onset indicating that other factors also influence AO. We examined AO in 148 individuals in 57 sibships from the SCA2 founder population in Cuba. The mutant CAG repeat allele explained 57% of AO variance. To estimate heritability of the residual variance after correction for SCA2 repeat length, we applied variance component analysis and determined the coefficient of intraclass correlation. We found that 55% of the residual AO variance was familial. To test candidate modifier alleles in this population, we selected 64 unrelated individuals from a set of 394 individuals who were highly discordant for AO after correction for SCA2 CAG repeat length. We hypothesized that long normal alleles in the other 8 polyQ disease genes were associated with premature disease onset in SCA2. Of the 8 genes tested, only long normal CAG repeats in the CACNA1A gene were associated with disease onset earlier than expected based on SCA2 CAG repeat size using non-parametric tests for alleles (P < 0.04) and genotypes (P < 0.023) after correction for multiple comparisons. CACNA1A variation explained 5.8% of the residual variation in AO. The CACNA1A calcium channel subunit represents an excellent candidate as a modifier of disease in SCA2. It is highly expressed in Purkinje cells (PCs) and is essential for the generation of the P/Q current and the complex spike in PCs. In contrast to other polyQ proteins, which are nuclear, the CACNA1A and SCA2 proteins are both cytoplasmic. Furthermore, small pathologic expansions of the polyQ domain in the CACNA1A protein lead to PC degeneration in SCA6. Future studies are needed to determine whether the modifier effect of CACNA1A relates to neuronal dysfunction or cell death of Purkinje neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000334     DOI: 10.1093/brain/awh586

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  50 in total

Review 1.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 2.  Molecular pathogenesis of spinocerebellar ataxia type 6.

Authors:  Holly B Kordasiewicz; Christopher M Gomez
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

3.  Two novel alleles of tottering with distinct Ca(v)2.1 calcium channel neuropathologies.

Authors:  T Miki; T A Zwingman; M Wakamori; C M Lutz; S A Cook; D A Hosford; K Herrup; C F Fletcher; Y Mori; W N Frankel; V A Letts
Journal:  Neuroscience       Date:  2008-07-01       Impact factor: 3.590

4.  Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms.

Authors:  A R Paciorkowski; Y Shafrir; J Hrivnak; M C Patterson; M B Tennison; H B Clark; C M Gomez
Journal:  Neurology       Date:  2011-08-31       Impact factor: 9.910

5.  ATXN3, ATXN7, CACNA1A, and RAI1 Genes and Mitochondrial Polymorphism A10398G Did Not Modify Age at Onset in Spinocerebellar Ataxia Type 2 Patients from South America.

Authors:  Fernanda S Pereira; Thais L Monte; Lucas D Locks-Coelho; Amanda S P Silva; Orlando Barsottini; José L Pedroso; Mario Cornejo-Olivas; Pilar Mazzetti; Clecio Godeiro; Fernando R Vargas; Maria-Angélica F D Lima; Hélio van der Linden; Maria Betânia Pereira Toralles; Paula F V Medeiros; Erlane Ribeiro; Pedro Braga-Neto; Diego Salarini; Raphael M Castilhos; Maria-Luiza Saraiva-Pereira; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

6.  Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Authors:  Ilya Bezprozvanny; Thomas Klockgether
Journal:  Drugs Future       Date:  2009-12       Impact factor: 0.148

Review 7.  Deranged calcium signaling in Purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias.

Authors:  Adebimpe Kasumu; Ilya Bezprozvanny
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

8.  A comprehensive clinical and genetic study of a large Mexican population with spinocerebellar ataxia type 7.

Authors:  L Velázquez-Pérez; C M Cerecedo-Zapata; O Hernández-Hernández; E Martínez-Cruz; Y S Tapia-Guerrero; R González-Piña; J Salas-Vargas; R Rodríguez-Labrada; R Gurrola-Betancourth; N Leyva-García; B Cisneros; J J Magaña
Journal:  Neurogenetics       Date:  2014-10-16       Impact factor: 2.660

9.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

10.  Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.

Authors:  Jing Liu; Tie-Shan Tang; Huiping Tu; Omar Nelson; Emily Herndon; Duong P Huynh; Stefan M Pulst; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.